The EFADchip® offers several advantages over current technologies: greater sensitivity, higher specificity, quantitative measurement, faster detection, multiplexing and cost savings. HKLife’s technology is protected by 9 worldwide patents and has gone through several generations of development, showing HKLife’s commitment to quality. EFADchip® is encased in a cartridge for better handling and integration into the BioRadar - G Series.
EFADchip simultaneously detects and identifies of bacterial, viral, fungal targets, antimicrobial resistance genes and patient immune status. EFADchip® employs an electric field to concentrate target nucleic acids, accelerating detection and removing the need for expensive and time-consuming amplification. Hybridization is accelerated from hours in passive processes to minutes by the electric field. When compared to passive hybridization, better discrimination between off target and on target signals is achieved. Signals are developed with staining with Nanogold particles and directly observed visually, eliminating the need for costly fluorescence detection. Pathogens are identified by comparing the hybridization signal pattern on the chip with a pattern map. EFADchip® quantifies hybridization events giving correlation between results and clinic.
HKLife’s first focus is pneumonia: it is highly infective, highly transmissible, and has a high mortality rates, mainly in the young (<5) and the old (>65). Pneumonia is an acute infection of the lungs and a cause of astronomical healthcare spending. HKLife’s EFADchip® Pneumonia detects the causative agent of pneumonia using sputum, saliva, blood, urine or faeces.
EFADchip® Pneumonia panel encompasses more than 70 bacterial, viral and fungal targets, including bacterial antimicrobial resistance genes. Using this broad spectrum of targets delivers a total solution in diagnosing pulmonary infections. This gives doctors fast comprehensive guidance away from empirical therapies and towards directed treatment.
HKLife has completely validated its bacterial panel. EFADchip® has a limit of detection for bacterial pathogens of 105 colony forming units (CFU) per milliliter, which is similar to what sputum samples contain, according to the American Thoracic Society. Extensive testing is being performed on real clinical samples with EFADchip®. The BioRadar - G Series is progressing towards clinical testing and is about to enter (C)FDA and CE applications.